Back to Journals » Therapeutics and Clinical Risk Management » Volume 15 » Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified
Please verify you are not a robot.